97 results about "Bradycardia" patented technology

The invention provides a disposable sensor patch for the non-invasive detection of heart disease. The patch is placed on a person's chest area for automatic analysis of ECG. The heart condition is indicated via an indicator integrated within the patch. The patch is inexpensive and simple for self-administration. In one embodiment, the status of the heart is indicated via multiple LEDs. The detection and indication typically occurs, within 24 hours or sooner if a condition is readily identifiable. The patch is thin, flexible, and incorporates a battery, ECG amplifier, and a processor for analyzing ECG waveform and indicating the heart condition. A software algorithm searches for a cardiac abnormality such as arrhythmia, bradycardia, tachycardia, fibrillation, mycocardial infarction, ischemia, long-QT syndrome, blocks, late potentials, and premature contractions. In another embodiment, results and relevant ECG data are stored in memory for later retrieval.

Systems and techniques are provided for controlling vagus nerve stimulation (VNS) delivered by an implantable medical device for mitigating heart failure in a patient. In one mode, VNS therapy is set to levels just below a heart rate reduction threshold so as to deliver VNS near the highest stimulation levels that can be achieved without reducing patient heart rate. In this manner, a maximum level of heart failure mitigation can be achieved via VNS therapy without incurring the potentially adverse consequences of inducing bradycardia within the patient. In another mode, VNS therapy is instead controlled to deliver VNS above the threshold so as to mitigate heart failure while also selectively reducing heart rate, as may be appropriate in patients susceptible to cardiac ischemia. A controlled heart rate reduction curve may additionally or alternatively be determined for use in achieving target amounts of heart rate reduction.

A system and method which employs atrial discrimination algorithms to distinguish between different atrial arrhythmias occurring in a patient for selecting an optimal pacing therapy corresponding to the type of arrhythmia identified. The invention may be implemented in a bradycardia pacemaker or other implantable cardiac device. In response to the detection of an atrial rate above the atrial tracking rate, discrimination criteria are applied to a detected atrial activity signal to distinguish between different types of supraventricular tachycardia, such as fast atrial flutter and other atrial flutter at a relatively slower rate, which may be occurring in the patient. The discrimination criteria may be, for example, rate-based or morphology based. The pacer is controlled to provide pacing therapy to a heart in a manner corresponding to the type of supraventricular tachycardia identified. For example, antitachycardia pacing may be provided to the heart in response to the detection of a relatively lower rate supraventricular tachycardia / other atrial flutter, whereas another pacing control, e.g., ventricular pacing, such as ventricular rate regulation or Rate Smoothing, may be applied if a more rapid rate supraventricular tachycardia / fast atrial flutter is identified. The output of an atrial discrimination algorithm may be tracked and the trend thereof used to improve therapy timing.

A power supply for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and far providing anti-bradycardia pacing energy to the heart, comprising a capacitor subsystem for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

Methods of medically treating a patient by the use of anti-bradycardia pacing using a totally subcutaneous, non-transvenous system. Some examples include the application of pacing pulses to a patient at a pacing rate that is above a predetermined level. One example of a totally subcutaneous, non-transvenous system includes a capacitor subsystem for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythnia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

An improved pacemaker has a hysteresis feature that activates accelerated pacing during periods of sinus arrest and / or extreme bradycardia. When the patient's intrinsic heart rate drops below a hysteresis rate, the pacemaker reverts to a programmable accelerated rate or to the average cardiac rate. Accelerated pacing is delivered for a programmable period of time, after which the pacing rate is gradually reduced toward a lower rate. If a desirable intrinsic rate is not attained after the pacing rate is reduced to the lower rate, the intervention cycle repeats.

A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and / or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.

A system and method for detecting and verifying bradycardia / asystole episodes includes sensing an electrogram (EGM) signal. The EGM signal is compared to a primary threshold to sense events in the EGM signal, and at least one of a bradycardia or an asystole is detected based on the comparison. In response to detecting at least one of a bradycardia or an asystole, the EGM signal is compared to a secondary threshold to sense events under-sensed by the primary threshold. The validity of the bradycardia or the asystole is determined based on the detected under-sensed events.

A power supply for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, comprising a capacitor subsystem for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

A method and system for operating a cardiac rhythm management device which employs pacing therapy to regularize the ventricular rhythm. Such ventricular rate regularization may be employed with conventional bradycardia pacing, ventricular resynchronization therapy, or anti-tachyarrhythmia therapy.

Methods for treating cardiac muscle disorders, such as cardiac arrhythmias, by administration of a neurotoxin to cardiac muscle are disclosed. Bradycardia can be alleviated for several months by a single intrapericardial or intracardiac injection or infusion of a botulinum toxin. Tachycardia can be alleviated by preganglionic sympathetic nervous system administration of a botulinum toxin.

A method and apparatus for treating or preventing neurocardiogenic syncope is disclosed. Upon detection of bradycardia or a drop in blood pressure indicating the onset of syncope, electrostimulation pulses are delivered during the heart's refractory period. The pulses are non-excitatory but increase myocardial contractility and thereby increase cardiac output.

A power supply for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, comprising a capacitor subsystem for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

The invention relates to an electrocardiosignal classifying method and device, electronic equipment and a storage medium. The electrocardiosignal classifying method includes the steps that a signal waveform is extracted from electrocardiosignals; the morphological characteristic of the signal waveform is obtained, wherein the morphological characteristic comprises any one of the width characteristic, the correction characteristic, the slope characteristic and the waveform depth characteristic; the morphological statistical characteristics of the morphological characteristic are obtained, and are input into a classifier; classification results input by the classifier are obtained, and the signal type of the electrocardiosignals is obtained. According to the technical scheme, abnormal rhythms of various types can be more accurately identified, it is avoided that abnormal rhythms of non-atrial-fibrillation types of tachycardia, bradycardia, arrhythmia and the like are mistakenly classified into abnormal rhythms of atrial-fibrillation types, and the accuracy of electrocardiosignal classifying is increased.

The invention relates to a method, a device, electronic equipment and a storage medium for electrocardiogram signal detection and classification. The method comprises the following steps of: extracting a signal waveform from an electrocardiogram signal; acquiring a morphological characteristic and a deep characteristic of the signal waveform, wherein the morphological characteristic comprises anyone of a TR wave amplitude difference characteristic, a PR wave quantity ratio characteristic, an ST wave band characteristic and a P wave variation characteristic, and the deep characteristic comprises a depth characteristic and a hierarchy characteristic; inputting the morphological characteristic and the deep characteristic into a classifier; and acquiring a classification result output by theclassifier so as to obtain the signal type of the electrocardiogram signal, wherein the classification result is a result that the classifier performs classification according to the morphological characteristic and the deep characteristic, and the signal type comprises an atrial fibrillation rhythm, a non-atrial fibrillation abnormal rhythm, a normal sinus rhythm and noise. The method can accurately identify various types of abnormal rhythms, avoids the situation that abnormal rhythms of non-atrial fibrillation types such as tachycardia, bradycardia and arrhythmia are classified into atrial fibrillation types in error, and improves the accuracy of classification of electrocardiogram signals.

A cardiac rhythm management device which employs pacing therapy to regularize the ventricular rhythm. Such ventricular rate regularization may be employed within bradycardia pacemakers, ventricular resynchronization devices, or implantable cardioverter / defibrillators.

A pacemaker system comprising apnea detecting means for measuring parameters about respiratory including at least two parameters of the number of apneas per unit time and the period of time during which an apnea continues and detecting an apnea state of a sleeping patient on the basis of the measured parameters, characterized in that when the measured values of the detection parameters measured by the apnea detecting means increase over reference values at which the pacing rate is changed to a preset and stored SAS treating pacing rate, the pacing rate is changed and the pacing mode is changed to an SAS treating pacing mode. The apnea syndrome of the sleeping patient is detected and treated coping with the bradycardia and various problems accompanying the apnea syndrome. The pacing rate and the pacing rate time can be set suitably for the patient without imposing too heavy a burden on the patient depending on the condition of the patient, and consequently the syndrome of the SAS can be treated efficiently and reliably.

A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier.wherein R is a hydrogen atom or P(═O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH═CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.

Techniques for detecting tachyarrhythmia and also for preventing T-wave oversensing use signals filtered by a narrowband bradycardia filter in combination with signals filtered by a narrowband tachycardia filter. A separate wideband filter may also be used.

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof.wherein each symbol is as defined in the specification.

Methods for the prevention, treatment or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

Disclosed is a 2-aminobutanol compound represented by the following formula (I)or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the 2-aminobutanol compound of formula (I). The 2-aminobutanol compounds of formula (I) have few side effects including bradycardia and have superior peripheral blood lymphocyte-decreasing effects.

The invention discloses a health management system with an electrocardiogram monitoring function. The health management system with the electrocardiogram monitoring function comprises an electrocardiogram monitoring component, a blood oxygen monitoring component, a safety indicating component, a six-axis motion sensor, a transmission component, a battery pack, a processor and a data storage module, wherein the electrocardiogram monitoring component, the blood oxygen monitoring component, the six-axis motion sensor and the battery pack are connected to the processor and the data storage module, and the processor and the data storage module are connected with the safety indicating component and the transmission component. The health management system with the electrocardiogram monitoring function has the advantages that difficulty in electrocardiogram monitoring is overcome, the problem that patients with cardiovascular diseases cannot be warned in case of abnormities such as irregular heart rate, cardiac arrhythmia, bradycardia and tachyrhythmia is solved; driver's electrocardiogram state detection is combined with judging analysis based on a fatigue driving algorithm, and a warning stimulation mode is adopted, so that accidents caused by fatigue driving is reduced; with recording and analyzing driver's electrocardiogram data during driving, driving habits are optimized and driving risks are reduced.

In one embodiment, a wearable defibrillation system may sense whether its wearer meets an unconscious bradyarrhythmia condition that can be associated with becoming unconscious. Even though such a condition might not be helped with a defibrillation pulse, the wearable-defibrillation system may still administer pacing pulses to prevent the bradycardia from becoming worse, such as a sudden cardiac arrest. In some embodiments, the pacing pulses are administered at a frequency too slow for the patient to regain consciousness. An advantage is that, because the patient remains unconscious, he does not experience the sometimes severe discomfort due to the pacing pulses.

The bradyrhythmia treating Chinese medicine is orally taken preparation obtained with astragalus root and aconite root as main material. Two types of pharmacodynamic bradyrhythmia model test, including amiodaronum rat and propranolol rat show that the bradyrhythmia treating Chinese medicine can raise the heart rate obviously and has no toxic side effect produced after being taken regularly.

The invention provides a physiotherapy shoe with medicinal treatment function. An insole of the shoe is provided with a groove in which containers in any number and any specifications are arranged; the bottoms of the containers are provided with container bases; the containers contain a composition selected from medicinal powder, liquid medicaments and volatile oil with medicinal treatment effect; and the medicaments can be percutaneously absorbed through a foot, have effects of promoting coronary circulation, activating cells, promoting blood circulation and microcirculation to be smooth and vigorous, and have functions of medicinal treatment and health care for human bodies. The physiotherapy shoe is suitable for ischemic chronic diseases such as diabetes mellitus and complications thereof, hypertension, coronary heart disease, bradycardia, cerebral infarction, cerebral thrombosis, cerebral apoplexy sequel, cervical spondylosis, lumbar, scapulohumeral periarthritis, rheumatism, rheumatoid arthritis, gout, femoral head necrosis, myasthenia of waist and legs, insomnia, constipation, benign prostatic hyperplasia, bronchitis, allergic asthma, allergic rhinitis, neurodermatitis, eczema, medicinal resh, anemia, gastritis, enteritis, kidney disorders, diseases of department of gynaecology and the like, can treat multiple diseases simultaneously, and has high recovery rate, safety and practicability, simpleness, convenience and easy implementation.

The invention relates to a method for preparing CNPase mutant zebra fish, and confirms that a mutant model can spontaneously generate bradycardia and even heart failure accompanied by severe heart failure. According to the invention, a CRISPR-Cas9 technology is combined with a microinjection technology, CNPase is specifically knocked out, a CNPase mutant F1 generation is prepared, and confirmation is performed through a Sange sequencing method; and through hybridizing and screening, a zebra fish homozygous mutant strain with heart specificity marked with green fluorescence is prepared, and it is confirmed that the CNPase homozygous mutant zebra fish can spontaneously generate cardiac hypertrophy and partially develop to heart failure through cardiology and kinetics indexes. The CNPase mutant zebra fish is prepared, an animal model is provided for researching functions of CNPase, and particularly great convenience is provided for researching related diseases of bradycardia accompanied by severe heart failure.